These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

829 related items for PubMed ID: 15139073

  • 1. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
    Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G.
    Cancer; 2004 May 15; 100(10):2261-8. PubMed ID: 15139073
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
    Liau CT, Chu NM, Liu HE, Deuson R, Lien J, Chen JS.
    Support Care Cancer; 2005 May 15; 13(5):277-86. PubMed ID: 15770489
    [Abstract] [Full Text] [Related]

  • 5. Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists.
    Majem M, Moreno ME, Calvo N, Feliu A, Pérez J, Mangues MA, Barnadas A.
    Support Care Cancer; 2011 Dec 15; 19(12):1983-90. PubMed ID: 21086141
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy.
    Rogers MP, Blackburn L.
    Clin J Oncol Nurs; 2010 Aug 15; 14(4):500-4. PubMed ID: 20682506
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V, Wan HS, Chan A.
    Ann Pharmacother; 2009 Mar 15; 43(3):444-52. PubMed ID: 19193584
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT, Raisch DW, Frost J.
    Cancer; 2006 Feb 15; 106(4):931-40. PubMed ID: 16404740
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
    Abbrederis K, Lorenzen S, Rothling N, Ihbe-Heffinger A, Schuster T, Peschel C, Lordick F.
    Onkologie; 2009 Feb 15; 32(1-2):30-4. PubMed ID: 19209016
    [Abstract] [Full Text] [Related]

  • 14. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.
    O'Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F.
    CMAJ; 1993 Aug 01; 149(3):296-302. PubMed ID: 8339175
    [Abstract] [Full Text] [Related]

  • 15. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Craver C, Gayle J, Balu S, Buchner D.
    J Med Econ; 2011 Aug 01; 14(3):341-9. PubMed ID: 21542674
    [Abstract] [Full Text] [Related]

  • 16. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM.
    J Support Oncol; 2003 Aug 01; 1(2):89-103. PubMed ID: 15352652
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.